Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2012; 3:7-13. doi:10.7150/jca.3.7 This volume Cite

Research Paper

Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials

Christopher H. Bailey1, Gayle Jameson1, Chao Sima2, Sharon Fleck1, Erica White1, Daniel D. Von Hoff1,2, Glen J. Weiss1,2 ✉

1. Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, Scottsdale, AZ, USA
2. The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA

✉ Corresponding author: Glen J. Weiss, MD, 10510 N. 92nd St., Ste 200, Scottsdale, AZ 85238. E-mail:gweissorg; Phone: (480) 323-1350; Fax: (480) 323-1359

Citation:
Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer 2012; 3:7-13. doi:10.7150/jca.3.7. https://www.jcancer.org/v03p0007.htm
Other styles

File import instruction

Abstract

Background: There is often a finite progression-free interval of time between one systemic therapy and the next when treating patients with advanced cancer. While it appears that progression-free survival (PFS) between systemic therapies tends to get shorter for a number of factors, there has not been a formal evaluation of diverse tumor types in an advanced cancer population treated with commercially-available systemic therapies.

Methods: In an attempt to clarify the relationship between PFS between subsequent systemic therapies, we analyzed the records of 165 advanced cancer patients coming to our clinic for consideration for participation in six different phase I clinical trials requiring detailed and extensive past medical treatment history documentation.

Results: There were 77 men and 65 women meeting inclusion criteria with a median age at diagnosis of 55.3 years (range 9.4-81.6). The most common cancer types were colorectal (13.9%), other gastrointestinal (11.8%), prostate (11.8%). A median of 3 (range 1-11) systemic therapies were received prior to phase I evaluation. There was a significant decrease in PFS in systemic therapy for advanced disease from treatment 1 to treatment 2 to treatment 3 (p = 0.002), as well as, from treatment 1 through treatment 5 (p < 0.001).

Conclusions: In an advanced cancer population of diverse tumor types, we observe a statistically significant decrease in PFS with each successive standard therapy. Identification of new therapies that reverse this trend of decreasing PFS may lead to improved clinical outcomes.

Keywords: Progression-free survival, chemotherapy, advanced cancer, systemic therapy, phase I clinical trials

Citation styles

APA
Bailey, C.H., Jameson, G., Sima, C., Fleck, S., White, E., Von Hoff, D.D., Weiss, G.J. (2012). Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. Journal of Cancer, 3, 7-13. https://doi.org/10.7150/jca.3.7.

ACS
Bailey, C.H.; Jameson, G.; Sima, C.; Fleck, S.; White, E.; Von Hoff, D.D.; Weiss, G.J. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J. Cancer 2012, 3, 7-13. DOI: 10.7150/jca.3.7.

NLM
Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer 2012; 3:7-13. doi:10.7150/jca.3.7. https://www.jcancer.org/v03p0007.htm

CSE
Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. 2012. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer. 3:7-13.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use